TRAVERE THERAPEUTICS, INC. Payment for Contingent Consideration Liability, Financing Activities
TRAVERE THERAPEUTICS, INC. (TVTX) reported Payment for Contingent Consideration Liability, Financing Activities of $863.00 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-03.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities · last filed 2023-08-03
- TRAVERE THERAPEUTICS, INC. payment for contingent consideration liability, financing activities for the quarter ending 2023-06-30 was $259.00K, a 57.12% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. payment for contingent consideration liability, financing activities for the quarter ending 2023-03-31 was $604.00K, a 9.45% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. payment for contingent consideration liability, financing activities for the quarter ending 2022-12-31 was $604.00K, a 85.05% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. payment for contingent consideration liability, financing activities for the quarter ending 2022-09-30 was $604.00K, a 9.31% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. payment for contingent consideration liability, financing activities for fiscal 2022 was $2.48M, a 59.39% decline from fiscal 2021.
- TRAVERE THERAPEUTICS, INC. payment for contingent consideration liability, financing activities for fiscal 2021 was $6.10M, a 20.19% decline from fiscal 2020.
- TRAVERE THERAPEUTICS, INC. payment for contingent consideration liability, financing activities for fiscal 2020 was $7.65M, a 125.74% increase from fiscal 2019.
- TRAVERE THERAPEUTICS, INC. payment for contingent consideration liability, financing activities for fiscal 2019 was $3.39M, a 65.15% decline from fiscal 2018.
| Period end | Payment for Contingent Consideration Liability, Financing Activities 3 month | Payment for Contingent Consideration Liability, Financing Activities 6 month | Payment for Contingent Consideration Liability, Financing Activities 9 month | Payment for Contingent Consideration Liability, Financing Activities 12 month |
|---|---|---|---|---|
| 2023-06-30 | $259.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $863.00K 10-Q · filed 2023-08-03 | $1.47M derived: sum of 3 quarters · filed 2023-08-03 | $2.07M derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | $604.00K 10-Q · filed 2023-05-04 | $1.21M derived: sum of 2 quarters · filed 2023-05-04 | $1.81M derived: sum of 3 quarters · filed 2023-05-04 | $2.42M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-12-31 | $604.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $1.21M derived: sum of 2 quarters · filed 2023-02-23 | $1.81M derived: sum of 3 quarters · filed 2023-08-03 | $2.48M 10-K · filed 2023-02-23 |
| 2022-09-30 | $604.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $1.21M derived: sum of 2 quarters · filed 2023-08-03 | $1.88M 10-Q · filed 2022-10-27 | $5.91M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-06-30 | $604.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $1.27M 10-Q · filed 2023-08-03 | $5.31M derived: sum of 3 quarters · filed 2023-08-03 | $5.98M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $667.00K 10-Q · filed 2023-05-04 | $4.71M derived: sum of 2 quarters · filed 2023-05-04 | $5.37M derived: sum of 3 quarters · filed 2023-05-04 | $6.04M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $4.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $4.71M derived: sum of 2 quarters · filed 2023-02-23 | $5.37M derived: sum of 3 quarters · filed 2023-02-23 | $6.10M 10-K · filed 2023-02-23 |
| 2021-09-30 | $666.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $1.33M derived: sum of 2 quarters · filed 2022-10-27 | $2.06M 10-Q · filed 2022-10-27 | $2.83M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $667.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.40M 10-Q · filed 2022-08-04 | $2.16M derived: sum of 3 quarters · filed 2023-02-23 | $2.95M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $732.00K 10-Q · filed 2022-05-05 | $1.49M derived: sum of 2 quarters · filed 2023-02-23 | $2.28M derived: sum of 3 quarters · filed 2023-02-23 | $3.07M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $762.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $1.55M derived: sum of 2 quarters · filed 2023-02-23 | $2.34M derived: sum of 3 quarters · filed 2023-02-23 | $7.65M 10-K · filed 2023-02-23 |
| 2020-09-30 | $785.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-29 | $1.58M derived: sum of 2 quarters · filed 2021-10-29 | $6.89M 10-Q · filed 2021-10-29 | $7.71M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $793.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $6.10M 10-Q · filed 2021-07-29 | $6.93M derived: sum of 3 quarters · filed 2022-02-24 | $7.77M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $5.31M 10-Q · filed 2021-05-06 | $6.13M derived: sum of 2 quarters · filed 2022-02-24 | $6.97M derived: sum of 3 quarters · filed 2022-02-24 | $7.79M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $826.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $1.67M derived: sum of 2 quarters · filed 2022-02-24 | $2.48M derived: sum of 3 quarters · filed 2022-02-24 | $3.39M 10-K · filed 2022-02-24 |
| 2019-09-30 | $840.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $1.66M derived: sum of 2 quarters · filed 2020-11-05 | $2.56M 10-Q · filed 2020-11-05 | $3.44M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $817.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $1.72M 10-Q · filed 2020-07-31 | $2.60M derived: sum of 3 quarters · filed 2021-03-01 | $3.50M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $905.00K 10-Q · filed 2020-05-11 | $1.78M derived: sum of 2 quarters · filed 2021-03-01 | $2.68M derived: sum of 3 quarters · filed 2021-03-01 | $3.56M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $879.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $1.77M derived: sum of 2 quarters · filed 2021-03-01 | $2.65M derived: sum of 3 quarters · filed 2021-03-01 | $9.72M 10-K · filed 2021-03-01 |
| 2018-09-30 | $895.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $1.78M derived: sum of 2 quarters · filed 2019-10-30 | $8.84M 10-Q · filed 2019-10-30 | $7.93M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-06-30 | $881.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $7.95M 10-Q · filed 2019-08-06 | $7.04M derived: sum of 3 quarters · filed 2020-02-24 | $8.79M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-03-31 | $7.07M 10-Q · filed 2019-05-07 | $6.16M derived: sum of 2 quarters · filed 2020-02-24 | $7.91M derived: sum of 3 quarters · filed 2020-02-24 | $10.10M derived: sum of 4 quarters · filed 2020-02-24 |
| 2017-12-31 | -$907.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $845.00K derived: sum of 2 quarters · filed 2020-02-24 | $3.03M derived: sum of 3 quarters · filed 2020-02-24 | $4.10M 10-K · filed 2020-02-24 |
| 2017-09-30 | $1.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $3.94M derived: sum of 2 quarters · filed 2018-11-01 | $5.01M 10-Q · filed 2018-11-01 | $11.18M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-06-30 | $2.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $3.25M 10-Q · filed 2018-08-03 | $9.43M derived: sum of 3 quarters · filed 2019-02-26 | $11.00M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-03-31 | $1.07M 10-Q · filed 2018-07-06 | $7.24M derived: sum of 2 quarters · filed 2019-02-26 | $8.81M derived: sum of 3 quarters · filed 2019-02-26 | |
| 2016-12-31 | $6.17M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $7.74M derived: sum of 2 quarters · filed 2019-02-26 | $10.51M 10-K · filed 2019-02-26 | |
| 2016-09-30 | $1.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $4.34M 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | $2.77M 10-Q · filed 2017-08-09 | |||
| 2015-12-31 | $3.10M 10-K · filed 2018-07-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |